Tango Therapeutics (TNGX) brings hope for MTAP-deleted cancer patients with FDA cleared TNG462

Tango Therapeutics (TNGX) a clinical-stage biotech company, announced a significant achievement as the company’s Investigational New Drug (IND) application for TNG462 was cleared by the U.S. Food and Drug Administration (FDA). TNG462 is a next-generation inhibitor that targets cancer cells with methylthioadenosine phosphorylase (MTAP) deletions and is the first of its kind to be cleared by the FDA.

The company also announced that TNG908 received Orphan Drug Designation (ODD) from FDA for the treatment of malignant glioma, which makes the company eligible for incentives like federal grants and tax credits. Tango Therapeutics (TNGX) is aiming to file IND for TNG260, a first-in-class CoREST inhibitor, in the first half of 2023 and TNG348, a novel USP1 inhibitor for treatment of BRCA1 and BRCA2-mutant cancers, in mid-2023. Tango Therapeutics is committed to discovering new drug targets and providing next-generation precision medicine for cancer treatment, with TNG462 and TNG908 being examples of the company’s innovative therapies that are not available elsewhere.

Tango Therapeutics (TNGX) is focused on developing therapies that target specific genetic mutations found in cancer, known as precision medicine. The clearance of TNG462 and the Orphan Drug Designation for TNG908 are significant milestones for the company as it brings these innovative therapies one step closer to being available for patients with MTAP-deleted cancers.

The IND clearance for TNG462 and the Orphan Drug Designation for TNG908 are important steps in the drug development process and pave the way for the company to begin clinical trials for these drugs. With the FDA’s clearance and Orphan Drug Designation, Tango Therapeutics is now able to move forward with testing these treatments in human patients.

Overall, Tango Therapeutics is making significant progress in its drug development efforts and is committed to providing innovative treatments for cancer patients. The clearance of TNG462 and the Orphan Drug Designation for TNG908 are important milestones for the company, and the company’s pipeline of precision medicine therapies is promising. Tango Therapeutics (TNGX) is on track to file IND for TNG260 and TNG348 in the near future, which will bring the company closer to making these treatments available to patients with cancer.

The post Tango Therapeutics (TNGX) brings hope for MTAP-deleted cancer patients with FDA cleared TNG462 first appeared on Premium Stock Alerts.